To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Lymphoma, Follicular Clinical Trial

— rituximab  

Official title:

A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02162771
• Other study ID #: CT-P10 3.3
• Secondary ID: 2013-004493-96
• Status: Completed
• Phase: Phase 3
• Start date: July 14, 2014
• Est. completion date: December 29, 2018

Study information

• Verified date: January 2020
• Source: Celltrion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Phase 3 prospective, randomised, parallel-group, active controlled, double blind, multicentre, international study with 2 coprimary endpoints designed to demonstrate equivalence in pharmacokinetics (Part 1), as well as noninferiority in efficacy (Part 2), of CT-P10 to Rituxan when coadministered with CVP and to assess efficacy and safety in patients with advanced (stage III-IV) FL. Part 1 and Part 2 of the study will run in parallel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: December 29, 2018
• Est. primary completion date: January 12, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is male or female older than 18 years.

2. Patient has histologically confirmed FL according to the World Health Organization 2008 classification (Jaffe 2009); grades 1 to 3a based on local laboratory review.

3. Patient has at least 1 measurable tumour mass that has not previously been irradiated, and the mass must be:

• greater than 1.5 cm in the longest dimension or

• between 1.1 and 1.5 cm in the longest dimension and greater than 1.0 cm in the shortest axis

4. Patient has confirmed CD20+ lymphoma, as assessed by local laboratory review. (Tissue obtained within 6 months before Day 1 of Cycle 1 will be reviewed by a central independent reviewer to detect pathological type.)

5. Patient has Ann Arbor stage III or IV disease.

Exclusion Criteria:

1. Patient has received rituximab (or a rituximab biosimilar), cyclophosphamide, or vincristine.

2. Patient has allergies or hypersensitivity to murine, chimeric, human or humanised proteins, cyclophosphamide, vincristine, or prednisone.

3. Patient has evidence of histological transformation to high-grade or diffuse large B-cell lymphoma.

4. Patient has known central nervous system involvement.

5. Patient has received previous treatment for NHL:

• Previous treatment including chemotherapy, radiotherapy, immunotherapy, and/or surgery (except previous biopsy)

• All doses of corticoid therapy for treatment of NHL

• Corticoid therapy during the previous 4 weeks from Day 1 of Cycle 1 with prednisone >20 mg per day for the treatment for any purpose

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Follicular

Intervention

Biological:
• Rituxan

• CT-P10

Drug:
• Cyclophosphamide

• Vincristine

• Prednisone

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Celltrion

References & Publications (1)

Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared wi — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Serum Concentration-time Curve at Steady State (AUCtau)	AUCtau: Area under the plasma drug concentration-time curve within a dosing interval at steady state.; PK sampling was done at pre-dose and 1 hour after the end of infusion (EOI) at Core Cycles 1-3 and 5-8. At Core Cycle 4 (i.e. steady state), intensive PK samplings were done as follows: predose, EOI, 1 hour after EOI, 24 hour after EOI, 168 hour after EOI, 336 hour after EOI, 504 hour after EOI. Lastly, one sample at any time of the end of treatment (EOT) 1 visit was obtained.	Core Cycle 4 (Week 12)
Primary	Maximum Serum Concentration at Steady State (Cmax,ss)	Cmax,ss: Maximum concentration of drug in plasma at steady state on administering a fixed dose at equal dosing intervals.; PK sampling was done at pre-dose and 1 hour after the end of infusion (EOI) at Core Cycles 1-3 and 5-8. At Core Cycle 4 (i.e. steady state), intensive PK samplings were done as follows: predose, EOI, 1 hour after EOI, 24 hour after EOI, 168 hour after EOI, 336 hour after EOI, 504 hour after EOI. Lastly, one sample at any time of the end of treatment (EOT) 1 visit was obtained.	Core Cycle 4 (Week 12)
Primary	Overall Response Rate (ORR) According to the 1999 International Working Group (IWG) Criteria	ORR was defined as the proportion of patients with the best response of complete response (CR), unconfirmed complete response (CRu), or partial response (PR) by central review.; Per 1999 IWG criteria, the disease status was assessed by using contrasted CT, and CR, CRu, and PR were defined as followings; CR=Disappearance of all clinical/radiographic evidence of disease: regression of lymph nodes to normal size, absence of B-symptoms, bone marrow involvement, and organomegaly, and normal LDH level; CRu=Regression of measurable disease: >=75% decrease in SPD of target lesions and in each target lesions. no increase in the size of non-target lesions, neither new lesion nor organomegaly measured; PR=Regression of measurable disease: >=50% decrease in SPD of target lesions and no evidence of disease progression.	During the Core Study Period (up to 8 cycles; Week 24)
Secondary	B-cell Kinetics (B-cell Depletion and Recovery)	B-cell kinetics were demonstrated by median values of B-cell counts (Lower limit of quantification was 20 cells/uL).	Cycles 1 to 8 during the Core Study Period

External Links

•   Related Info